Pyrimethamine market

Pyrimethamine Market, by Indication (Toxoplasmosis, Malaria, and Others), by Route of Administration (Parenteral and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Feb 2022
CMI4948
178 Pages
Excel & Pdf
Pharmaceutical

Summary

Pyrimethamine is listed as one of the top drugs on the World Health Organization's essential drugs list. Pyrimethamine selectively inhibits the Plasmodium form of dihydrofolate reductase and reduces the production of folic acid, which is necessary for the synthesis of Plasmodium's nucleic acid. The ability of pyrimethamine to cure protozoan infections and toxoplasma infections, an increase in the number of human immunodeficiency virus (HIV) patients worldwide, and immunosuppressed people at the risk of infection are some of the factors that are expected to drive the development of the pyrimethamine market during the forecast period.

The global pyrimethamine market is estimated to be valued at US$ 1,106.8 million in 2022 and expected to increase to US$ 1,655.1 Mn by 2030, witnessing a CAGR of 5.2% over the forecast period (2022-2030).

Figure 1. Global Pyrimethamine Market Share (%), By Region, 2022

The rising prevalence of toxoplasmosis infection is expected to drive the growth of the global pyrimethamine market.

Toxoplasmosis is an infection caused by a single-celled parasite called Toxoplasma gondii. The rising prevalence of toxoplasmosis infection is expected to drive the growth of the global pyrimethamine market. As per the sources of the Centers for Disease Control and Prevention (CDC) 2018, in the U.S., an estimated 11% of the 6-year-old population was infected with Toxoplasma gondii. In different places around the world, it is estimated that over 60% of people have been infected with Toxoplasma gondii. The infection rate is generally higher in areas with high heat, humidity, and lower altitudes, as oocysts survive better in these types of environments.

Pyrimethamine Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 1,106.8 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	5.2%	2030 Value Projection:	US$ 1,655.1 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Indication: Toxoplasmosis, Malaria, Others By Route of Administration: Parenteral, Oral By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Vyera Pharmaceuticals, LLC, Cerovene Healthcare PVT LTD, GlaxoSmithKline plc, Impax Laboratories, Inc., NCBO BioPortal, Pfizer, Inc., PRN Pharmacal, SUDA Pharmaceuticals, Taj Accura Pharmaceuticals, TargetMo Chemicals Inc., Evaluate Ltd., and Abcam
Growth Drivers:	Increase in the number of HIV patients worldwide Rising prevalence of toxoplasmosis infection Rising prevalence of malaria Rising cancer cases and chemotherapy procedures
Restraints & Challenges:	Possible side effects associated with pyrimethamine High cost of pyrimethamine

Figure 2. Global Pyrimethamine Market Share (%) Analysis, By Route of Administration, 2022

Global Pyrimethamine Market – Regional Analysis

North America is expected to dominate the global pyrimethamine market due to an increase in the number of cancer cases (as pyrimethamine can induce apoptosis of cancer cells) and chemotherapy procedures in the region. For instance, according to the 2019-2021 Cancer Survival and Treatment Data and Data Report released by the American Cancer Society, as of January 1, 2019, the estimated number of cancer cases in the U.S. was approximately 16,920,370.

Global Pyrimethamine Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID 19) pandemic and consequent lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. The coronavirus pandemic has also hindered the development, production, and supply of medicines and other healthcare products and affected the growth of the healthcare business of many companies around the world. Therefore, during the forecast period, the impact of the COVID19 pandemic is also expected to limit the growth of the global pyrimethamine market.

Global Pyrimethamine Market: Restraint

Possible side effects associated with pyrimethamine include occasional and possibly serious hypersensitivity reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and homophenylalanine amines, which are expected to hamper the market growth. Also, the high cost of pyrimethamine is expected to restrain the global pyrimethamine market growth over the forecast period. For instance, the price of Daraprim (pyrimethamine) is very high. In 2018, the list price for a one-month supply (60 tablets) in the U.S. was almost US$45,000.

Key Players

Major players operating in the global pyrimethamine market include Vyera Pharmaceuticals, LLC, Cerovene Healthcare PVT. LTD, GlaxoSmithKline plc, Impax Laboratories, Inc., NCBO BioPortal, Pfizer, Inc., PRN Pharmacal, SUDA Pharmaceuticals, Taj Accura Pharmaceuticals, TargetMo Chemicals Inc., Evaluate Ltd., and Abcam.

Table of Content

*Browse 35 market data tables and 29 figures on “Global Pyrimethamine Market” - Global forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2022-2030)?

The global pyrimethamine market is estimated to be valued at US$ 1,106.8 Million in 2022 and expected to exhibit a CAGR of 5.2% between 2022 and 2030.

What are the major factors driving the market growth?

An increase in the number of HIV patients worldwide, rising prevalence of toxoplasmosis infection, rising cancer cases and chemotherapy procedures, and rising prevalence of malaria are major growth driving factors for the market.

Which is the major route of administration segment in the market?

Oral route is the major route of administration segment in the market.

What are the key factors hampering the growth of the market?

Possible side effects associated with pyrimethamine and the high cost of pyrimethamine are the major factor restraining the market growth.

Which are the major players operating in the market?

Major players operating in the market include Vyera Pharmaceuticals, LLC, Cerovene Healthcare PVT. LTD, GlaxoSmithKline plc, Impax Laboratories, Inc., NCBO BioPortal, Pfizer, Inc., PRN Pharmacal, SUDA Pharmaceuticals, Taj Accura Pharmaceuticals, TargetMo Chemicals Inc., Evaluate Ltd., and Abcam.